Avance® Nerve Graft and Advances in Peripheral Nerve Repair to be Featured at American Society for Surgery of the Hand 2012

Share Article

AxoGen to support educational events at ASSH 2012 featuring presentations by clinical experts on use of pioneering regenerative technologies in peripheral nerve repair.

AxoGen Logo

“We are committed to providing education about advances in the surgical treatment of peripheral nerve injuries and are pleased to have several clinical experts in nerve repair participating in our educational forums at ASSH.” Karen Zaderej, AxoGen CEO

AxoGen, Inc. (OTCBB: AXGN), a leader in the science and commercialization of surgical solutions for peripheral nerve repair, announced today that Avance ® Nerve Graft, a processed nerve allograft for surgical repair and reconstruction of peripheral nerve segmental defects, will be featured in two educational forums at the American Society for Surgery of the Hand 2012 Meeting, September 6 – 8 in Chicago.

“Clinical use of Avance® Nerve Graft continues to expand,” said Karen Zaderej, CEO for AxoGen. “We are committed to providing education about advances in the surgical treatment of peripheral nerve injuries and are pleased to have several clinical experts in nerve repair participating in our educational forums at ASSH.”

Avance® Nerve Graft is the only commercially available processed nerve allograft for surgically repairing peripheral nerve discontinuities. By eliminating a second surgery to harvest the patient’s own nerve tissue for use in the repair, Avance® Nerve Graft offers surgeons and patients an alternative to traditional autograft nerve repair procedures.

Educational events sponsored by AxoGen at ASSH include:
ASSH Forum 21: Hands-On Lab and Workshop: Application of Regenerative Medicine Technologies for Nerve Injuries
Faculty: James P. Higgins, MD, Steven L. Moran, MD
Thursday, September 6, 2012 from 6:30 - 8:00 p.m.

ASSH Forum 23: Panel Discussion: State of the Union in Peripheral Nerve Repair
Moderator: Ivica Ducic, MD, PhD, Panelists: Bauback Safa MD, MBA, FACS, Peter Tang, MD, MPH, Erick DeVinney, BS, Director of Clinical and Translational Sciences
Friday, September 7, 2012 from 7:00 - 8:00 a.m.

In addition to sponsoring educational forums, AxoGen will be exhibiting its technologies and products at Booth 1112 at the ASSH meeting.

About AxoGen, Inc.
AxoGen (OTCBB: AXGN) is a regenerative medicine company dedicated to advancing the science of peripheral nerve repair and commercializing next generation surgical technologies. The Company’s portfolio of proprietary products and technologies offers new options for surgical nerve repair and reconstruction. Every day, people suffer traumatic injuries and damage caused by disease and prior surgery that impacts the function of their peripheral nerves. Peripheral nerves provide the pathways for both motor and sensory signals throughout the body and their damage can result in the loss of function and feeling. AxoGen’s products offer a full suite of surgical nerve repair solutions including Avance® Nerve Graft, the only commercially available process nerve allograft nerve for bridging nerve discontinuities of 5mm to 70mm in length, AxoGuard® Nerve Connector, a coaptation aid allowing for close approximation of severed nerves gaps up to 5mm in length, and AxoGuard® Nerve Protector, a bioscaffold used to reinforce a coaptation site, wrap a partially severed nerve or isolate and protect nerve tissue.

AxoGen brings the science of nerve repair to life with thousands of surgical implants of AxoGen products and technology performed in hospitals and surgery centers across the United States, including military hospitals serving U.S. service men and women.

AxoGen is the parent of its wholly owned operating subsidiary, AxoGen Corporation. AxoGen’s principal executive office and operations are located in Alachua, FL.

To receive email alerts directly from AxoGen, please click here http://www.axogeninc.com/emailalerts.html .

Cautionary Statements Concerning Forward-Looking Statements
This Press Release contains “forward-looking” statements as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management’s current expectations or predictions of future conditions, events or results based on various assumptions and management’s estimates of trends and economic factors in the markets in which we are active, as well as our business plans. Words such as “expects”, “anticipates”, “intends”, “plans”, “believes”, “seeks”, “estimates”, “projects”, “forecasts”, “may”, “should”, variations of such words and similar expressions are intended to identify such forward-looking statements. The forward-looking statements may include, without limitation, statements regarding product development, product potential or financial performance. The forward-looking statements are subject to risks and uncertainties, which may cause results to differ materially from those set forth in the statements. Forward-looking statements in this release should be evaluated together with the many uncertainties that affect AxoGen’s business and its market, particularly those discussed in the risk factors and cautionary statements in AxoGen’s filings with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and actual results may differ materially from those projected. The forward-looking statements are representative only as of the date they are made, and AxoGen assumes no responsibility to update any forward-looking statements, whether as a result of new information, future events or otherwise.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Greg Freitag, Chief Financial Officer
Visit website